-

Half-year Liquidity Contract Statement for MEDINCELL

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between MEDINCELL (Paris:MEDCL) and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:

- 16,161 shares

- € 314,681.05

- Number of executions on buy side on semester: 627

- Number of executions on sell side on semester: 708

- Traded volume on buy side on semester: 66,789 shares for € 624,998.07

- Traded volume on sell side on semester: 69,983 shares for € 669,428.60

As a reminder :

• the following resources appeared on the last half year statement on 30 June 2021 on the liquidity account:

- 19,355 shares

- € 270,935.67

- Number of executions on buy side on semester: 706

- Number of executions on sell side on semester: 705

- Traded volume on buy side on semester: 76,603 shares for € 926,491.56

- Traded volume on sell side on semester: 75,802 shares for € 958,751.11

• the following resources appeared on the liquidity account when the activity started:

- 0 shares

- € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

o0o

 

Buy Side    

 

Sell Side    

 

Number of
executions

Number of
shares

Traded volume
in EUR

 

Number of
executions

Number of
shares

Traded volume
in EUR

Total

627

66,789

624,998.07

 

708

69,983

669,428.60

01/07/2021

5

600

5,490.00

 

-

-

-

02/07/2021

5

201

1,829.10

 

2

201

1,869.30

07/07/2021

1

200

1,800.00

 

-

-

-

08/07/2021

7

600

5,280.00

 

-

-

-

09/07/2021

-

-

-

 

2

207

1,863.00

12/07/2021

-

-

-

 

2

117

1,057.68

14/07/2021

1

200

1,760.00

 

1

76

687.04

15/07/2021

-

-

-

 

5

400

3,620.00

20/07/2021

5

700

6,202.00

 

-

-

-

26/07/2021

10

400

3,620.00

 

-

-

-

27/07/2021

10

182

1,667.12

 

7

600

5,520.00

28/07/2021

1

18

164.88

 

3

400

3,740.00

29/07/2021

2

395

3,732.75

 

7

436

4,163.80

30/07/2021

7

606

5,641.86

 

6

207

1,966.50

02/08/2021

9

800

7,360.00

 

4

377

3,524.95

03/08/2021

3

400

3,580.00

 

1

1

9.00

04/08/2021

1

200

1,760.00

 

9

305

2,735.85

05/08/2021

1

200

1,788.00

 

4

294

2,648.94

06/08/2021

-

-

-

 

5

600

5,472.00

09/08/2021

5

600

5,430.00

 

2

400

3,632.00

10/08/2021

4

347

3,129.94

 

3

200

1,820.00

11/08/2021

3

253

2,277.00

 

8

600

5,478.00

12/08/2021

11

400

3,628.00

 

3

200

1,820.00

13/08/2021

4

260

2,347.80

 

-

-

-

16/08/2021

8

341

3,075.82

 

7

601

5,469.10

17/08/2021

1

1

9.12

 

1

1

9.12

18/08/2021

3

401

3,693.21

 

10

801

7,393.23

19/08/2021

6

800

7,248.00

 

3

44

399.52

20/08/2021

1

1

9.07

 

2

21

190.68

23/08/2021

-

-

-

 

13

936

8,583.12

24/08/2021

4

600

5,430.00

 

4

200

1,840.00

25/08/2021

1

1

9.14

 

1

1

9.14

27/08/2021

1

200

1,808.00

 

1

2

18.40

30/08/2021

4

400

3,740.00

 

34

4,355

42,461.25

31/08/2021

-

-

-

 

1

41

430.50

01/09/2021

3

600

6,282.00

 

10

1,759

19,296.23

02/09/2021

6

800

8,200.00

 

-

-

-

03/09/2021

3

307

3,152.89

 

6

601

6,250.40

06/09/2021

17

2,019

20,028.48

 

5

800

8,104.00

07/09/2021

3

475

4,621.75

 

2

128

1,267.20

08/09/2021

-

-

-

 

2

20

198.00

09/09/2021

13

1,400

13,356.00

 

10

652

6,291.80

10/09/2021

11

600

5,694.00

 

-

-

-

13/09/2021

6

800

7,448.00

 

1

200

1,880.00

14/09/2021

1

200

1,848.00

 

-

-

-

16/09/2021

-

-

-

 

9

1,000

9,500.00

17/09/2021

29

3,072

29,061.12

 

8

1,600

15,664.00

20/09/2021

14

1,328

11,872.32

 

2

400

3,592.00

21/09/2021

-

-

-

 

5

368

3,341.44

22/09/2021

-

-

-

 

24

2,032

19,222.72

23/09/2021

10

1,200

11,304.00

 

5

600

5,826.00

24/09/2021

6

600

5,514.00

 

1

2

19.00

27/09/2021

3

401

3,637.07

 

3

11

102.96

28/09/2021

3

600

5,370.00

 

-

-

-

29/09/2021

3

317

2,799.11

 

-

-

-

30/09/2021

11

1,353

11,662.86

 

-

-

-

01/10/2021

2

330

2,778.60

 

1

161

1,400.70

04/10/2021

-

-

-

 

1

27

229.77

05/10/2021

-

-

-

 

5

400

3,472.00

07/10/2021

1

200

1,700.00

 

-

-

-

08/10/2021

1

42

354.48

 

-

-

-

11/10/2021

13

1,958

16,094.76

 

5

400

3,308.00

12/10/2021

-

-

-

 

2

200

1,660.00

13/10/2021

-

-

-

 

17

2,000

17,160.00

14/10/2021

3

102

877.20

 

2

143

1,266.98

15/10/2021

1

1

8.85

 

1

1

8.85

18/10/2021

14

1,299

10,937.58

 

-

-

-

20/10/2021

1

200

1,648.00

 

-

-

-

21/10/2021

-

-

-

 

18

2,058

17,863.44

22/10/2021

6

800

7,160.00

 

12

1,079

9,786.53

25/10/2021

-

-

-

 

28

2,433

22,675.56

26/10/2021

22

2,200

20,504.00

 

6

989

9,642.75

27/10/2021

-

-

-

 

44

4,200

39,732.00

28/10/2021

1

200

1,952.00

 

25

2,400

23,832.00

29/10/2021

18

2,400

22,896.00

 

-

-

-

01/11/2021

20

2,200

21,648.00

 

23

3,200

32,416.00

02/11/2021

24

3,200

30,656.00

 

7

800

7,864.00

03/11/2021

17

2,001

18,949.47

 

19

2,200

21,076.00

04/11/2021

15

2,041

18,899.66

 

14

1,244

11,606.52

05/11/2021

14

1,671

15,172.68

 

8

1,149

10,524.84

08/11/2021

4

552

5,061.84

 

10

808

7,562.88

09/11/2021

2

135

1,247.40

 

5

799

7,478.64

10/11/2021

-

-

-

 

17

2,200

21,230.00

11/11/2021

-

-

-

 

7

1,200

12,096.00

12/11/2021

5

600

6,090.00

 

17

1,000

10,360.00

15/11/2021

11

1,000

10,040.00

 

3

400

4,160.00

16/11/2021

-

-

-

 

2

200

2,040.00

18/11/2021

2

400

3,968.00

 

-

-

-

19/11/2021

7

600

5,874.00

 

-

-

-

23/11/2021

10

1,000

9,620.00

 

-

-

-

24/11/2021

13

1,200

11,364.00

 

2

293

2,783.50

25/11/2021

3

200

1,880.00

 

1

107

1,016.50

26/11/2021

7

674

6,241.24

 

1

200

1,912.00

29/11/2021

-

-

-

 

9

1,000

9,640.00

30/11/2021

3

200

1,900.00

 

1

1

9.56

01/12/2021

-

-

-

 

3

5

47.80

02/12/2021

9

1,000

9,740.00

 

21

1,994

19,640.90

03/12/2021

10

1,000

9,580.00

 

1

200

1,960.00

06/12/2021

-

-

-

 

13

1,200

11,688.00

07/12/2021

12

1,180

11,469.60

 

6

800

7,824.00

08/12/2021

7

1,015

9,703.40

 

-

-

-

09/12/2021

13

1,401

13,183.41

 

7

400

3,792.00

10/12/2021

6

399

3,750.60

 

4

218

2,062.28

13/12/2021

2

300

2,859.00

 

9

982

9,417.38

14/12/2021

3

600

5,670.00

 

6

600

5,742.00

15/12/2021

16

1,201

11,253.37

 

2

2

18.96

16/12/2021

2

105

966.00

 

3

401

3,781.43

17/12/2021

-

-

-

 

1

6

57.00

20/12/2021

7

800

7,536.00

 

9

933

8,891.49

21/12/2021

1

200

1,880.00

 

4

400

3,792.00

22/12/2021

1

1

9.44

 

19

1,600

15,488.00

23/12/2021

6

800

7,680.00

 

3

400

3,852.00

24/12/2021

2

201

1,917.54

 

2

201

1,929.60

27/12/2021

8

1,200

11,508.00

 

10

801

7,793.73

28/12/2021

7

600

5,760.00

 

8

639

6,172.74

29/12/2021

6

800

7,728.00

 

3

400

3,904.00

30/12/2021

3

201

1,917.54

 

4

344

3,309.28

31/12/2021

-

-

-

 

13

1,368

13,461.12

MEDINCELL

Public limited company with a capital of € 221 683.48
Registered office: 3 rue des Frères Lumière 34830 Jacou
444 606 750 R.C.S. on the Montpellier Trade and Companies Register

Contacts

MEDINCELL

MEDINCELL

BOURSE:MEDCL

Release Versions

Contacts

MEDINCELL

More News From MEDINCELL

Medincell Announces Successful c. €48 Million Private Placement

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or Japan Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced the successful pricing of its Private Placement (as defined below) for a total amoun...

Medincell Launches a Private Placement for International Institutional Investors

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the “Company”), today announced the launch of a private placement of approximately 6% of the Company’s share capital...

Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation to the 2026 Leerink Global Healthcare Conference and Jefferies Biotech on the Beach Summit in Miami, Florida, March 8 – 11, 2026. Meetings with Christophe Douat, Chief Executive Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, may be arranged v...
Back to Newsroom